HaTay Pharmaceutical boosts capital with new share issuance

HaTay Pharmaceutical JSC (HNX:DHT) has announced the results of its share issuance, raising share capital from owners' equity. The company issued 8,233,778 shares, translating to a 10:1 ratio where existing shareholders received one new share for every ten held. This issuance was approved by the board of directors on October 30, 2025.

The capital increase is sourced from retained earnings and share premium from the company’s 2024 audited financial statements. Specifically, 22,300,000,000 dong will be drawn from retained earnings, and 60,040,260,000 dong from share premium. The total capital increase amounts to 82,340,260,000 dong.

Following the issuance, the total outstanding shares of HaTay Pharmaceutical JSC as of October 27, 2025, increased to 90,575,551 shares. Any fractional shares resulting from the distribution were canceled, and new shares are expected to be delivered between November and December 2025.